Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,301–1,400 of 1,676
(2000) · Time to knit · doi:10.1016/j.ccol.2015.05.026 · Cited by 2
Secondary Prevention of Coronary Artery Disease
Watson, K. E., Guo, Y., & Sahni, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00030-3 · Cited by 3
Characterization of a peptide containing the major heparin binding domain of human hepatic lipase
Coady, B. M., Marshall, J. D., Hattie, L., et al. (2018) · Journal of Peptide Science · doi:10.1002/psc.3123 · Cited by 2
High-Density Lipoprotein and High-Density Lipoprotein Cholesterol
Riggs, K. A., & Rohatgi, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00006-5 · Cited by 2
Updated management for patients with cardiovascular disease and diabetes
Dugan, J. A., Butts, A., Collins, B. S., Saini, P. S., & Bradley, S. (2019) · JAAPA · doi:10.1097/01.jaa.0000569804.46658.ce · Cited by 2
Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
Arnold, S. V., GOSCH, K. L., Wong, N. D., Hejjaji, V., Goyal, A., Leiter, L. A., & Kosiborod, M. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.126 · Cited by 1
Primary Prevention of Coronary Artery Disease
Bhattacharya, R., & Natarajan, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_5 · Cited by 2
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 4
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 3
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_3 · Cited by 2
Management of Hyperlipidemia in 2015
Feingold, K. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch24 · Cited by 2
WENGER, N. K. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.040 · Cited by 2
Watson, K. E., & Wiesner, P. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002675 · Cited by 2
Mulick, A. R., Prieto‐Merino, D., Tillin, T., Havulinna, A. S., Shipley, M. J., Valera‐Gran, D., Gentry‐Maharaj, A., Ryan, A., Kumari, M., Jukema, J. W., et al. (2020) · medRxiv · doi:10.1101/2020.03.02.19010173 · Cited by 2
Liu, H., Wang, F., Li, Y., Xia, H., Pan, D., Yang, L., Wang, S., & Sun, G. (2020) · Preprints.org · doi:10.20944/preprints202010.0563.v1 · Cited by 1
“However, some studies have shown that the use of drugs that increase plasma HDL levels, such as niacin and cholesterol ester transfer protein inhibitors, do not increase the clinical benefits in patients with CVD [19,20].”
BackgroundInfluentialGinsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-4 · Cited by 2
Nakhaee, S., & Mehrpour, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00113-5 · Cited by 2
Yasmin, S., Yadav, A. K., Michael, R. H., Khatun, S., Chauhan, S., Kurmi, M. K., Kaur, S., Haider, N., Sah, A. K., Kumar, A. S., et al. (2023) · Preprints.org · doi:10.20944/preprints202308.1553.v1 · Cited by 2
Risk Factors for Atherosclerotic Cardiovascular Disease
Weidner, C., & Braun, L. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_4 · Cited by 3
The Role of level and function of High Density Lipoprotein (HDL) in Cardiovascular Diseases
آقاسی زاده, م., غیور مبرهن, م., کاظمی, ط., آوان, ا., & Miri‐Moghaddam, E. (2020) · مجله علمی دانشگاه علوم پزشکی بیرجند · doi:10.32592/jbirjandunivmedsci.2020.27.2.100 · Cited by 2
Combined lipid-lowering therapy
Karásek, D. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.169 · Cited by 1
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_2 · Cited by 1
Mirshekari, M., Zargaran, A., Shirzad, N., Hemmatabadi, M., Khanavi, M., Ebrahimpur, M., Afra, F., & Namazi, S. (2022) · Pharmaceutical Sciences · doi:10.34172/ps.2022.36 · Cited by 1
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Diabetes and Atherogenic Dyslipidemia
Mooradian, A. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_40 · Cited by 1
Clinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 3
Sherratt, S. C. R., Libby, P., Bhatt, D. L., & Mason, R. P. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-41192-2_17 · Cited by 1
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1
Carotid intima-medial thickness in patients with severe hypertriglyceridemia
Ahmad, M., Kennedy, B. A., Son, S., McIntyre, A. D., Lazarte, J., Wang, J., & Hegele, R. A. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.04.001 · Cited by 1
“However, clinical trials of cardiovascular outcomes using TG-lowering agents such as omega-3 fatty acids [15,16], extended-release niacin [17] and fibrates [18] have been equivocal.”
BackgroundZhao, W., Wang, Y., Li, J., Chen, T., Yin, D., Dai, H., Yao, Z., & Zhao, S. (2024) · Lipids · doi:10.1002/lipd.12406 · Cited by 1
Lan, N. S. R., & Watts, G. F. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000879 · Cited by 1
Raja, A., Shafique, M. A., Raja, S., Mustafa, M. S., Shuja, M. H., Ahmed, M., Alim Ur Rahman, H., & Asghar, M. S. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001877 · Cited by 1
Malick, W. A., Rosenson, R. S., Naidu, I., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_5 · Cited by 3
Masana, L., Torné, P., García–Moll, X., Dalli, E., & Amigó, N. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104199 · Cited by 1
Das, A., Khatun, S., Banerjee, A., et al. (2025) · Synthesis · doi:10.1055/a-2681-4862 · Cited by 1
Shi, J., Swanson, S. A., Diemer, E. W., Gerlovin, H., Posner, D. C., Wilson, P. W. F., Gaziano, J. M., Cho, K., Hernán, M. Á., & Program, O. B. O. T. V. M. V. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf190 · Cited by 4
Cao, Y., Meng, X., Xu, X., Xia, C., Yang, C., Cui, X., He, Q., & Song, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01828 · Cited by 1
Lipid metabolism disorders in metabolic syndrome
Polyakova, E. A. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6539 · Cited by 1
Hata, K., Okada, T., Takahashi, M., Arimatsu, Y., Kawahira, J., Murakami, K., Harada, A., Yoshikawa, N., Inamatsu, M., & Kakuni, M. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07515-6 · Cited by 1
VLDL cholesterol and ASCVD risk: A population-based study
Balling, M., Roepstorff, O. G., Gerds, T. A., Varbo, A., Langsted, A., Mortensen, M. B., Smith, G. D., Nordestgaard, B. G., & Afzal, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.024 · Cited by 1
U-Shaped Lipid-CVD Links in Older Adults
Ye, X., Du, S., Chen, S., Shi, Y., Wang, W., Wan, Y., Wang, J., Zeng, J., Pan, C., Yang, S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102544 · Cited by 2
A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques
Fukase, T., & Dohi, T. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00104-x · Cited by 2
Tsai, Y. H., Kumarihamy, M., Ponce, N. B., Alam, M. M., Kim, W., Yu, X. B., Kim, T. K. J., & Samia, A. C. S. (2026) · ACS Applied Engineering Materials · doi:10.1021/acsaenm.5c01089 · Cited by 3
Li, X., Wang, Z., Liang, J., Li, B., Meng, Q., & Gao, M. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001794 · Cited by 1
Nordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 3
Correa, Y., Felderer, B., Jansen, M., Gil‐Carton, D., Blanchet, C. E., Roosen‐Runge, F., Pedersen, J. S., & Cárdenas, M. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152016 · Cited by 1
Habib, A., Khan, M. S. M., Aneeq, A., Tahir, H. B., Mehmoodi, A., Malik, J., & Perveen, A. (2026) · Clinical Cardiology · doi:10.1002/clc.70305 · Cited by 2
“Experiences with previous HDL‐targeted therapies highlight the complexity of translating biological insights into effective clinical treatments [23, 24, 34].”
Myśliwiec, A., Leksa, D., Bartusik‐Aebisher, D., & Aebisher, D. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.007 · Cited by 1
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 2
Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19071071 · Cited by 2
“Niacin has been shown to reduce Lp(a) levels by more than 30% [64]; however, evidence from AIM-HIGH (ClinicalTrials.gov: NCT00120289) [65] and the HPS2-THRIVE (ClinicalTri-als.gov: NCT00461630) [66] showed no cardiovascular benefit.”
Lipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
Epelde, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908850 · Cited by 1
Mafham, M., Zayed, M., Collins, R., Sabatine, M. S., Armitage, J., Brittain, D. E. A., da Costa, B. R., Chen, F., Goonasekera, M. A., Hill, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107546 · Cited by 21
Aydoğan, M., Yavuz, M. L., Yalçın, E., Özer, P. K., & Emet, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166400 · Cited by 2
Therapeutic Options: Lifestyle Measures and Pharmacological Approaches
Wilkinson, I. B., & King, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-14556-3_29 · Cited by 1
Placing HPS2-THRIVE in context using Bayesian analysis
Labos, C., Brophy, J. M., & Thanassoulis, G. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.156 · Cited by 1
“When HPS2-THRIVE is incorporated with the results of the previous ER-niacin trials the estimate for cardiovascularmortality is OR 0.95 (95% CrI 0.86–1.06).”
BackgroundInfluentialVariance in niacin response in individuals with elevated lipoprotein(a)
Safarova, M. S., & Владиславович, Е. М. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.007 · Cited by 1
The appropriate clinical use of niacin in the treatment of dyslipidemia
Houston, M. C., Guarneri, M., & Kahn, J. (2015) · Clinical Lipidology · doi:10.2217/clp.14.60 · Cited by 1
Toth, P. P. (2015) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2015-110253 · Cited by 1
Gotto, A. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.004 · Cited by 1
Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman, W. H. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.06.027 · Cited by 1
Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents
Gotto, A. M., & Pownall, H. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_28 · Cited by 1
“E vents (HPS2-THRIVE) trial raise additional doubts regarding niacin [ 46 ].”
BackgroundStudy of Coronary Risk Factors in Rural Malaysia Population
Aye, M., Cabot, J. S. F., & Sazali, M. F. (2015) · International Journal of Medical Biology · doi:10.4303/ijmb/235922 · Cited by 1
Low-density lipoprotein cholesterol goals: still not in patients' best interest
Mayer, M. G. (2016) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2016-110383 · Cited by 1
“HPS2-THRIVE was concerning for increases in several adverse outcomes (eg, gastrointestinal, musculoskeletal, infectious and serious bleeding) among those receiving extended-release niacin and laropiprant.(11) Additionally concerning was the 0.”
BackgroundMethodResultInfluentialIcosabutate, a More Potent Form of Omega 3 Fatty Acids, Shows Promise in Lowering Triglycerides
Riesen, W. F. (2016) · Cardiology · doi:10.1159/000445286 · Cited by 1
How important are triglycerides as risk factors?
D’Addato, S., Palmisano, S., & Borghi, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000438 · Cited by 1
Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease
Almarzooq, Z., & Singh, P. (2016) · InTech eBooks · doi:10.5772/64762 · Cited by 2
The Regression of Atherosclerosis: The Power of Multimodality Imaging
Feig, J. E. (2015) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000369 · Cited by 1
Platelet Prostanoids and their receptors
Fries, S., & Großer, T. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_15 · Cited by 1
Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders
Lee, J.-H., & Hegele, R. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1311784 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 3
Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease
Aronow, W. S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.106
“Compared with placebo, niacin-laropiprant did not reduce cardiovascular events but increased serious adverse events (9).”
BackgroundMethodInfluentialDrugs That Affect Lipid Metabolism
Beckett, R. D., Wilhite, A. L., Robinson, N., & Rosene, A. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.005 · Cited by 2
Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
“Based on approximations from past large CV outcomes trials including or limited to patients with T2DM, the populations under investigation in some of these new and ongoing studies of patients who are on statins are large: In past studies, roughly 25% to 40% of patients had TG levels of 150 mg/dL or higher and LDL-C le…”
Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia
Evans, M. C., Stalam, T., & Miller, M. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1013-8 · Cited by 2
Cholesteryl Ester Transfer Protein Inhibitors – Future Soon to be REVEALed
Huggins, C., Charolidi, N., & COCKERILL, G. W. (2015) · European Cardiology Review · doi:10.15420/ecr.2015.10.01.64 · Cited by 1
Primary and Secondary Prevention of Cardiovascular Disease
Bader, B., & Schwartz, R. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-89725-7_4 · Cited by 1
Lipoprotein(a)—It Is Risky, but What Do We Do About It?
Després, A.-A., & Arsenault, B. J. (2018) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-018-0592-7 · Cited by 1
Controversial Issues in the Treatment of Dyslipidemias in Patients with Diabetes Mellitus
Parhofer, K. G. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002574 · Cited by 1
The Role of Niacin in the Management of Dyslipidemia†
Keenan, J. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.052 · Cited by 1
Choudhary, M. K., Sun, R., Dahal, S. S., Bhattarai, R., Nepal, R., & Zhang, Y. (2020) · Journal of Clinical and Preventive Cardiology · doi:10.4103/jcpc.jcpc_9_20 · Cited by 1
Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids)
Evans, M. C., & Miller, M. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_15 · Cited by 2
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-44203-7_21 · Cited by 1
Wang, P., Liu, Z., Liu, X., Sun, J., Qian, Z., & Xu, X. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00502-w · Cited by 1
HDL colesterol, protector de enfermedad cardiovascular: calidad vs. cantidad
Stoll, A. I. (2019) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.05.01.011 · Cited by 1
Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years
Seo, Y.-H., & Shin, H. (2022) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2022.54.2.95 · Cited by 1
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.11.009 · Cited by 2
Hyperlipidemia management: A calibrated approach
Firnhaber, J. M. (2023) · The Journal of Family Practice · doi:10.12788/jfp.0576 · Cited by 1
Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions
Ward, N. C., Loh, W. J., & Watts, G. F. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_14 · Cited by 2
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Názara-Otero, C., Argüeso, R. M., Pedro‐Botet, J., Pintó, X., Millán, J., Seijo, M. P., Fernández, P. A., Ameneiros, M. E., del Alamo, A., Rodríguez, A., et al. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.002 · Cited by 3
Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual
Olmo, M. R. F., & Llergo, J. T. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00011-0 · Cited by 2
Chronic Kidney Disease and Its Clinical Correlates in a Rural Community in Southwestern Nigeria
Oni, O. O., Akinwusi, P., Owolabi, J. I., Odeyemi, A. O., Israel, G. M., Ala, O. A., Akande, J. O., Durodola, A. O., Israel, O. K., Ajibola, I., et al. (2022) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.390257 · Cited by 2
Research Progress on Hyperlipidemia
李, 成. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141235 · Cited by 2
Cholesterol, Atherosclerosis, Lipid-Lowering Therapy. Is It Completely Clear?
Vasiliev, A. P., & Streltsova, N. N. (2024) · Ural Medical Journal · doi:10.52420/umj.23.2.131 · Cited by 1
Lipid Management in Human Immunodeficiency Virus
Myerson, M. L. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.003 · Cited by 1
Reducing cardiovascular risk in type 2 diabetes mellitus
Preiss, D., & Sattar, N. A. (2014) · Medicine · doi:10.1016/j.mpmed.2014.10.011 · Cited by 2
Viejos y nuevos hipolipemiantes
Deibe, F. I. L., Gestal, I. B., Zamora, G. V., & Gómez, L. O. (2016) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.07.007 · Cited by 1
Titus-Rains, K. S., Cantrell, M. A., Egge, J. A., Alexander, B., Shaw, R. F., & Argo, T. R. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150665 · Cited by 1
Managing Chronic Coronary Artery Disease in Patients with Diabetes
Marx, N., & Reith, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00024-8 · Cited by 1
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.